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Abstract
Background—Children with high-functioning autism spectrum disorders (ASD) are at high risk 
for developing significant anxiety. Anxiety can adversely impact functioning across school, home 
and community environments. Cognitive behavior therapies (CBT) are frequently used with 
success for children with anxiety symptoms. Modified CBT interventions for anxiety in children 
with ASD have also yielded promising results.
Methods—Fifty children with high-functioning ASD and anxiety were randomized to group 
CBT or Treatment as Usual (TAU) for 12 weeks. Independent Clinical Evaluators, blind to 
condition, completed structured interviews (Anxiety Disorders Interview Schedule – Parent 
Version; ADIS-P) pre- and post-intervention condition.
Results—Forty-seven children completed either the CBT or TAU condition. Results indicated 
markedly better outcomes for the CBT group. Significant differences by group were noted in 
Clinician Severity Ratings, diagnostic status, and clinician ratings of global improvement. In the 
intent-to-treat sample, ten of 20 children (50%) in the CBT group had a clinically meaningful 
positive treatment response, compared to 2 of 23 children (8.7%) in the TAU group.
Conclusions—Initial results from this rigorously designed treatment study suggest that a group 
CBT intervention specifically developed for children with ASD may be effective in decreasing 
anxiety. Limitations of this study include small sample size, lack of an attention control group, and 
use of outcome measures normed with typically developing children.
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INTRODUCTION
Youth with autism spectrum disorders (ASD) are at increased risk for developing co-
occurring mental health conditions, and anxiety symptoms are among those most commonly 
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reported (Brereton, Tonge & Einfeld, 2006; Skokauskas & Gallagher, 2011). In fact, high 
rates of co-morbid psychopathology have been found in a population-derived sample 
(Simonoff et al., 2008), as well as community and clinic-based samples of youth with ASD 
(Bruin, Ferdinand, Meester, Nijs & Berheij, 2007; Leyfer et al., 2006). A majority of 
children in these samples met diagnostic criteria for a DSM Axis I diagnosis (72–80%), and 
anxiety disorders were among the most commonly reported concurrent diagnoses.
The impact of anxiety symptoms may be felt across contexts and can interfere significantly 
with a child’s ability to participate in home, school and community settings (Russell & 
Sofronoff, 2005). The presence of significant anxiety symptoms place individuals at risk for 
unemployment, substance abuse, and other psychiatric problems (Velting, Setzer, & Albano, 
2004). Anxious youth may experience marked difficulties in social interaction and in family 
relationships. They may also perform below their ability level, affecting overall school 
performance and participation in after school activities (Langley, Bergman, McCracken, & 
Piacentini, 2004; Weissman, Antinoro, & Chu, 2009; Wood, 2006). Furthermore, anxiety 
may exacerbate the core-deficits of ASD, magnifying social inappropriateness, repetitive 
questioning, and ritualized behavior (Brereton et al., 2001; Greenway & Howlin, 2010). In 
the general population, very few children with clinical anxiety experience recovery without 
intervention (Hudson, Krain & Kendall, 2001), and given the vulnerability of children with 
ASD, the same may be true for them (Brereton et al., 2001).
Cognitive-behavioral treatments (CBT) are well-established, highly researched evidenced-
based treatments, and are considered to be the gold standard psychosocial treatment for 
anxiety in children and adults (Olatunji, Cisler, & Deacon, 2010; Silverman, Pina & 
Viswesvaran, 2008; Walkup, et al., 2008). As CBT has been increasingly identified as an 
effective treatment approach for mental health symptoms in typically developing youth, 
researchers have begun applying CBT approaches to other populations, including youth with 
ASD, with encouraging findings. The results of individual case studies (Reaven & Hepburn, 
2003; Sze & Wood, 2007), small group studies (Reaven et al., 2009; White, Ollendick, 
Scahill, Oswald & Albano, 2009), and randomized clinical trials (Chalfant, Rapee, & 
Carroll, 2007; Sofronoff, Attwood, & Hinton, 2005; Sung et al., 2011; Wood et al., 2009) 
have demonstrated reductions in anxiety after the implementation of modified CBT 
techniques.
Clinician-researchers using CBT with children with ASD and anxiety recognize that the 
social, cognitive and linguistic complexities of children with ASD may limit the 
accessibility of therapeutic interventions (Reaven et al., 2009). For example, challenges with 
motivation, social understanding and imagination, atypical ways of demonstrating or 
reporting anxiety, difficulties with self-regulation, the presence of rigid thought processes, 
and poor generalization abilities may all impede therapeutic understanding (Ozsivadjian & 
Knott, 2011). To address these challenges, common modifications to protocols for children 
with ASD include: concrete and visual teaching strategies, multiple choice lists, drawing, 
creative outlets for expression, and video modeling for hard-to-teach concepts (Moree & 
Davis, 2010; Reaven et al., 2009). Finally, incorporation of children’s special interests and 
an emphasis on parent participation have been suggested as important to include in treatment 
protocols for youth with ASD (Moree & Davis, 2010; Reaven et al., 2009; Wood et al., 
Reaven et al. Page 2
J Child Psychol Psychiatry. Author manuscript; available in PMC 2015 April 10.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2009). Parent involvement may be particularly beneficial for children with ASD, as their 
participation may enhance generalizability of skills across settings (Puleo & Kendall, 2010; 
Reaven, 2011).
Both individual (Wood et al., 2009) and group CBT treatment modalities (Chalfant et al., 
2007; Reaven et al., 2009; Sofronoff et al., 2005) have been effective for children with ASD, 
although head-to-head comparisons have yet to occur. Some researchers suggest a 
combination of both individual and group modalities in order to provide children with ASD 
explicit as well as incidental social practice in protective and supportive settings (White et 
al., 2009). Previous group CBT treatment studies for youth with ASD have emphasized 
anxiety management strategies such as relaxation techniques and cognitive strategies, rather 
than graded exposure approaches (Sofronoff et al., 2005; Sung et al., 2011), a key ingredient 
of CBT interventions for anxiety (Kendall & Hedtke, 2006). Other researchers implemented 
CBT protocols originally developed for typically developing children, and modified them 
for youth with ASD (Chalfant et al., 2007). Woods and colleagues (2009) used a modular 
approach to target friendship skills and adaptive behavior deficits, in addition to targeting 
anxiety symptoms. Parents were included in several of these programs (Chalfant et al., 2007; 
Sofronoff et al., 2005; Woods et al., 2009); anxiety education was a focus of their 
participation. Parents were also encouraged to serve as “co-therapists” or coaches, to support 
the delivery of interventions.
The purpose of the present study was to extend our previous work, examining the efficacy of 
a family-focused group CBT program developed specifically for children with ASD and 
clinical anxiety, allowing for the presence of additional co-occurring mental health 
symptoms. In the initial treatment study using the Facing Your Fears (FYF) protocol (Facing 
Your Fears: Group Therapy for Managing Anxiety in Children with High-Functioning 
Autism Spectrum Disorders; Reaven, Blakeley-Smith, Nichols & Hepburn, 2011), results 
indicated significant reductions in parent-reported anxiety symptoms for children with ASD, 
relative to a wait list control group (Reaven et al., 2009). Limitations (i.e., lack of random 
assignment and independent evaluation) limited the generalizability of these findings. The 
current study was designed to correct these difficulties by implementing randomized 
assignment and using Independent Clinical Evaluators (ICEs) blind to condition to conduct 
pre- and post-assessments. It was hypothesized that children who received the active 
treatment (FYF) would demonstrate reductions in anxiety severity, decreases in the number 
of pre-treatment anxiety diagnoses, and display overall improvement in anxiety symptoms 
from baseline levels, relative to children in the Treatment-As-Usual (TAU) condition.
METHODS
Participants
The intent-to-treat (ITT) sample included 50 youth with ASD between the ages of 7 and 14 
years with a participating parent. There were no pre-treatment differences in the 
demographic composition of the two groups. See Table 1.
Participants were recruited through IRB-approved study announcements which were mailed 
to local parent groups, schools, and clinics. Project clinicians also conducted several 
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community outreach activities to build awareness of the study for families and educators. 
Informed consent and assent was obtained for all participants prior to collecting any data. 
See Figure A (Consort Flow Diagram).
Inclusion criteria for child participants was: (1) chronological age between 7–14 years; (2) a 
confirmed diagnosis of an ASD, determined by one of three expert clinical psychologists 
(JR, SH, ABS) based upon review of a recent (within one year or newly administered) 
Autism Diagnostic Observation Schedule (ADOS; Lord et al., 1999) and the Social 
Communication Questionnaire (SCQ; Berument, et al., 1999); (3) speaking in full, complex 
sentences (required for completion of Module III of the ADOS), and as reflected in recent 
standardized cognitive assessment1, and (4) clinically significant symptoms of anxiety, 
defined as a score above the clinical significance cutoff on separation (SEP) social (SOC) 
and/or generalized anxiety (GAD) subscales of the Screen for Child Anxiety and Related 
Emotional Disorders—parent version (SCARED; Birmaher et al., 1999).
Participants were excluded: (1) if the child’s primary psychiatric symptoms were determined 
by the ICE to be reflective of another condition such as depression or psychosis. (2) if the 
child did not demonstrate “group readiness” in the first three sessions of FYF, as 
demonstrated by the child’s ability to separate from his parent without marked disruptive 
outbursts; and (3) if one parent could not commit to attending 80% of sessions.
Procedure
This study was completed in compliance with the Colorado Multiple Institutional Review 
Board. Families initiated contact with the research clinic and a research assistant explained 
the goals and procedures of the study. If the study was of interest to the parent, the research 
assistant reviewed the inclusion criteria and conducted a brief telephone screen for 
eligibility. If the child was a potentially eligible participant, the family was invited to the 
research clinic for one or two sessions in which they completed the ASD diagnostic 
measures (e.g., ADOS and SCQ), standardized cognitive testing (if available either through 
previous research visits or school testing), the SCARED (completed separately with parents 
and children), and additional measures not reported in this study. If a child met diagnostic 
criteria for an ASD, spoke in full, complex sentences, and obtained scores above the clinical 
significance cutoff on SEP, SOC, and/or GAD subscales of the SCARED, the parent was 
invited for an additional session to complete an ADIS-P. Families were compensated for 
their participation in the assessment activities.
Once a cohort of 8–12 eligible families was qualified and pre-intervention measures 
collected, participants were randomly assigned to either the TAU or FYF condition using a 
computer-generated assignment system. Families not randomized to the FYF intervention 
were offered an opportunity to participate in the intervention at the end of the TAU 
condition. The intervention conditions began an average of 12 days (4–18 days) after 
completion of the pre-intervention measure (ADIS-P). Parents were asked to report on the 
child’s medications and other treatments received throughout the study period, regardless of 
1Verbal IQ cutoff was originally set at 80; clinicians evaluated participants who had a VIQ less than 80 to determine appropriateness 
for participation. Three treatment completers had VIQs below 80 (range: 70–80).
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condition assignment. Attendance and acceptability measures were collected only from the 
FYF participants. Each condition was 12–16 weeks long, to accommodate family schedules 
and provide 12 therapy sessions for the FYF condition. Intervention time period was 
matched within each cohort.
Within two to six weeks of the last session of the FYF condition or the equivalent time 
period for the TAU condition, the ADIS-P was re-administered by an ICE, who was 
unaware of the participant’s treatment condition. Families were specifically instructed not to 
tell the ICE whether they were in the FYF or TAU condition. At approximately 3 and 6 
months after the post-intervention assessment, parents and youth who received the FYF 
treatment were asked to complete the SCARED by mail.
Attendance—Twenty-four children entered the FYF intervention and 3 dropped out for a 
completion rate of 87.5%. Approximately 85% of children missed one session or less.
Conditions
Treatment-As-Usual (TAU): Families assigned to TAU maintained their current 
intervention programs and were allowed to pursue new programs as they wished during the 
4-month intervention period. The families were contacted monthly to track the services and 
medications their child received (See Table 1). Of the 23 youth in the TAU condition, 6 
(26.1%) took medications targeting anxiety symptoms, 16 (69.6%) participated in social 
skills interventions, 6 (26.1%) participated in bully-proofing programs through school, 4 
(17.4%) participated in individual psychosocial interventions targeting coping or emotion 
regulation, and 2 (8.7) participated in family-focused interventions to address behavioral 
issues. After approximately 12 weeks (time matched to FYF group), the families completed 
post-intervention measures and were invited to participate in an upcoming FYF group. 
Ninety-three percent of families agreed (25 children) and enrolled in a FYF group.2
Facing Your Fears (FYF): The intervention consisted of 12 multi-family group sessions, 1 
½ hours in duration, supported by a set of manuals for the facilitators, parents, and youth. 
Groups were comprised of three to six children and parents, with a mode of 4. Each session 
included large-group activities (children and parents together), small-group activities 
(children together; parents together), and dyadic work (parent/child pairs). One clinical 
psychologist led each group, supported by two co-therapists (trainees in clinical 
psychology). Thirteen clinicians facilitated 12 groups over the course of the study. New 
group facilitators participated in an introductory training and were provided with the FYF 
manual and selected research articles, and received ongoing supervision by co-authors of the 
FYF intervention (JR & ABS).
The FYF intervention was written and developed specifically for children with ASD. 
However, the FYF program incorporated the important components of prior empirically 
supported programs (e.g., Coping Cat; Kendall & Hedtke, 2006), while making appropriate 
adaptations for youth with high-functioning ASD. CBT components such as graded 
2Results of their participation in FYF will be presented elsewhere.
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exposure, relaxation and deep breathing, strategies for emotion regulation, and use of 
cognitive self-control (Kendall, 1994; Silverman et al., 2008) were included in the FYF 
intervention. Given the social, emotional, communication and cognitive challenges of 
children with ASD, the delivery of the core concepts was modified to enhance accessibility 
of the material (see below).
Child Component: The 12 group sessions included: (1) an introduction to anxiety 
symptoms and common CBT strategies, (2) a focus on the implementation and 
generalization of specific strategies to treat anxiety (i.e., expanding calming and relaxing 
activities, recognizing automatic negative thoughts and developing coping statements). 
Children and parents were also engaged in graded exposure tasks (facing fears a little at a 
time). Finally, FYF included opportunities for social skills development embedded within 
group activities and exposure hierarchies (Reaven et al. 2011).
Parent Component: Core components were: (1) psycho-education regarding anxiety 
symptoms and CBT strategies; (2) parent coaching to support child participation, (3) 
discussion of the interaction between parental anxiety, parenting style and the maintenance 
of anxiety symptoms; and (4) discussion of the social and communicative challenges 
inherent in ASD and how these challenges may contribute to a protective parenting style 
(Reaven & Hepburn, 2006). Two types of “protection” were discussed: “adaptive” and 
“excessive”. “Adaptive protection” was defined as the ability to understand a child’s 
cognitive, physical, and emotional difficulties and strengths, and appropriately titrate 
exposure to challenging environmental events based on the child’s abilities. Parents who 
“excessively” protect may inadvertently limit their child’s exposure to anxiety-provoking 
situations by allowing the child to avoid anxious situations, even when the child possesses 
the requisite skills to be successful, thus maintaining anxious symptoms (Reaven & 
Hepburn, 2006).
Modifications for Children with ASD: To maintain attention and enhance participation, 
careful pacing of each session, a token reinforcement program for in-group behavior, and 
provision of visual structure and predictability of routine were put in place. Additional 
adaptations included: 1) use of worksheets combined with multiple choice lists; 2) written 
examples of core concepts; 2) hands-on activities; 3) emphasis on creative outlets for 
expression; 4) focus on strengths and special interests; 5) multiple opportunities for 
repetition and practice; 6) video modeling and a specific video activity (e.g., creating 
movies) to enhance generalization of concepts; and (7) a detailed parent curriculum (Reaven 
et al., 2011).
Eligibility Measures
Diagnosis of ASD: Diagnostic status was determined by expert clinical review of the ADOS 
(Lord et al, 1999), the SCQ (Berument et al., 1999) and documented using a symptom 
checklist based on the DSM-IV TR (APA, 2004). In all 50 ITT cases, a clinical psychologist 
(SH or ABS) also reviewed the data and either concurred or flagged the case for a consensus 
discussion. Three cases were flagged and consensus was reached; all three children met 
criteria for an ASD.
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The ADOS is a semi-structured, play-based direct assessment of social and communicative 
behaviors indicative of ASD. All lab personnel were trained to 85% reliability on the full 
range of scores. Assessments were videotaped and reliability assessed for 28% of ADOS 
administrations; kappa on ASD classification (on/off spectrum) was .92. The SCQ is a 40 
item parent report measure that taps history and current symptoms of autism. The SCQ has 
good specificity (.80) and sensitivity (.96), (Berument et al., 1999).
Screening for Cognitive Functioning: All potential participants lacking standardized 
cognitive testing within the past three years were administered the Wechsler Abbreviated 
Scales of Intelligence (WASI; Wechsler, 2002) to help determine eligibility.
Screening for Anxiety Symptoms: The SCARED (parent and child versions) was used 
primarily as an eligibility measure to determine whether the youth presented with elevated 
symptoms of SEP, SOC or GAD. It was also used as an outcome measure for follow up at 3 
and 6 months post-intervention because of ease of administration. The SCARED (Birmaher 
et al., 1999) is a 41-item inventory with five anxiety subscales (Panic, GAD, SEP, SOC, and 
School Anxiety) and a Total Score on a scale of 0–2. The SCARED was modified so that 
parents and children reported on symptoms over the past two weeks rather than the past 3 
months. In addition, items were read to children and visual cues were provided to aid 
comprehension.
Outcome Measures—The Anxiety Disorders Interview Schedule for Children-Parent 
Version (ADIS-P; Silverman & Albano, 1996) was administered before and after the 
intervention period for children in both conditions (FYF vs. TAU). The ADIS-P has been 
used in intervention research for children with and without ASD (Walkup et al., 2008; Wood 
et al., 2009). It is a best-practice, semi-structured psychiatric interview that assesses the 
presence of anxiety disorders as well as other co-occurring mental health conditions. ICEs, 
blind to the participant’s condition, conducted the interviews with the parent, determined 
relevant diagnostic classifications across DSM-IV categories, and provided summary codes 
of severity and interference, called “Clinician Severity Ratings” (CSRs, 0=no symptoms, 
8=very severe impairment).
ADIS-P administration training involved scoring above 80% reliability on clinical diagnoses 
and CSRs on three videotaped administrations of the ADIS-P and three live administrations 
(serving as the interviewer). The ADIS-P was administered by clinical psychologists (n=4) 
and advanced trainees in psychology (n=2) in a standardized manner before and after the 
intervention period. Agreement of CSRs with consensus ratings was adequate for all anxiety 
disorders studied (Intraclass correlation: SEP: .82; SOC: .88; Specific phobia (SpP): .86; 
GAD: .84. Reliability of clinical diagnoses determined from the ADIS-P were assessed in 16 
(37.2% of interviews) by a second ICE, consensus was obtained if there was disagreement, 
and all kappas were over .84.
The Clinical Global Impressions Scale – Improvement ratings (CGIS-I; Guy & Bonato, 
1976) were compiled by ICEs after the participants had completed all study activities and 
were in the follow-up phase of the project. These ratings were derived in a manner very 
similar to the methods described in previous studies (Walkup et al., 2008; Woods et al., 
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2009). The ICE reviewed a de-identified record that included the ADIS-P and the SCARED 
data obtained before and after the FYF and TAU conditions. The ICE provided a rating on a 
scale of 1–7 concerning the overall impression of improvement during that time period (i.e., 
1 indicated “very much improved”, 4 indicated “no change,” and 7 indicated “very much 
worse”). Children obtaining CGIS-I of 1 or 2 were considered to be positive treatment 
responders. The ICE was completely blind to treatment condition. Agreement between the 
ICE and the consensus improvement ratings was .86.
RESULTS
Of the 50 participants in the ITT sample, there were 47 treatment-completers. Due to issues 
with timing and administration of ADIS-P interviews, 43 participants completed ADIS-P 
data before treatment (n=20 for FYF; n=23 for TAU). See Table 1 for participant 
characteristics of the ITT sample. Three participants dropped out of the FYF condition prior 
to the completion of the FYF intervention. To account for the attrition, a “last observation 
carried forward (LOCF)” procedure was implemented. That is, baseline data was carried 
forward for the three participants and substituted for outcome data to allow the participants’ 
data to remain in the analyses. The LOCF procedure may result in a conservative estimate of 
true effect size, but is appropriate for an ITT sample, to limit bias that could result by 
analyzing treatment completers only.
Pre-treatment comparisons of participant characteristics
The comparability of the two intervention groups prior to treatment was assessed using chi-
square tests for categorical variables and t-tests for continuous variables. There were no 
statistically significant differences in the two groups on demographic or diagnostic variables 
before intervention (See Table 1).
Psychiatry complexity of participants
Children in both conditions were psychiatrically complex; there were no significant 
differences between groups in the number of psychiatric diagnoses. Psychiatric diagnoses 
(in addition to ASD) ranged from 1–7 (M= 5.10) for children in the FYF condition, and 2–8 
(M=4.65) for children in the TAU condition. The most common non-anxiety diagnostic 
categories were Attention Deficit Hyperactivity Disorder, Disruptive Disorders, and Mood 
Disorders.
Adherence to FYF Intervention
Trained research assistants watched videotaped or live sessions and completed a checklist 
rating the therapists’ adherence to the FYF protocol. Of the 144 intervention sessions 
conducted (12 groups, 12 sessions each), 42 sessions were coded for fidelity (i.e., 29.2%): 
82% met criteria of including 85% or more of the required session elements and 97.6% met 
criteria of including 80% or more of required session elements. Reliability of fidelity 
checklists was completed on 28% of sessions by two independent coders and was found to 
be excellent (ICC= .96).
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Acceptability of the FYF Intervention
Parents and children completed a Satisfaction Questionnaire post-intervention. Thirty-four 
children and 38 parents completed the measure within two weeks of finishing the 
intervention.3 Parents rated 17 different activities and children rated 10 different activities; 
on average, 72% of respondents found the activities overall to be “very helpful”. Only an 
average of 4.7% parents and 9.9% children found the activities “not helpful” overall.
Medications
Medication use was comparable by treatment condition. During the 3-month treatment 
period, no medications targeting anxiety or mood were added or terminated in either group; 
however, there were dosage reductions reported for two children in the FYF condition and 1 
child in the TAU condition (See Table 1).
Treatment Outcome
ITT analyses were conducted for three outcome variables: (1) CSRs generated for the four 
principal diagnoses by the ICE blind to the child’s assigned condition; (2) diagnostic status 
of the principal anxiety diagnoses per ADIS-P criteria; and (3) CGIS-Improvement ratings. 
For the three children who dropped out, baseline scores were carried forward to post-FYF/
post-TAU. Separate analyses were conducted for the ITT sample and for treatment 
completers. All statistically significant group differences were maintained across both 
analyses.
Clinician Severity Ratings (CSRs)—ANCOVA was used to test group differences in 
anxiety severity and interference, using pre-intervention CSRs as the covariate. CSR ratings 
are presented in Table 2. In the ITT analysis, significant differences by group were found for 
post-intervention CSRs in all four principal diagnoses: SEP, F(1, 40) = 4.21, p = .047; SOC, 
F(1, 40) = 6.04, p = .02; SpP, F(1, 40) = 14.45, p = .0001; and GAD, F(1, 40) = 8.11, p = .
007. CSRs were lower in the FYF group post-intervention. Effect sizes ranged from medium 
to large.
Diagnostic Status of Principal Anxiety Disorders—ANCOVA was used to test 
group differences in the number of principal anxiety disorders by group, with the baseline 
number of anxiety diagnoses entered as a covariate. For the ITT sample, children in the FYF 
condition demonstrated a significant reduction in overall number of anxiety disorders, F(1, 
42) = 5.39, p = .03. A significant reduction in diagnostic status did not occur in the TAU 
condition.
Chi-square tests were used to assess group differences in the absence/presence of principal 
anxiety diagnoses at post-intervention. There was a statistically significant reduction in 
GAD diagnoses in the FYF group, X2(1,42)=6.64, p=.01; effect size = .85, reflecting a large 
effect. There were no differences by group in diagnostic status for the remaining principal 
diagnoses: SEP, X2(1,42) = .48, p=.49; SOC, X2 (1,42) = .13, p=.72; or SpP, X2(1,42) = 
1.01, p=.32.
3Participants in the TAU Condition who completed the FYF Intervention are also included.
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CGIS-Improvement ratings—CGIS-I scores of 1 or 2 reflected “a clinically meaningful 
improvement in anxiety severity”, consistent with the work of other researchers in this area 
(Walkup et al., 2008; Woods et al., 2009). For the ITT sample, ten of 20 children (50%) in 
the FYF group and 2 of 23 children (8.7%) in the TAU group obtained a CGIS-I reflecting a 
positive treatment response, which is a statistically significant difference by group, X2(1,42) 
= 9.07, p = .003., with a large effect size (d=1.03).
Follow-up
Families in the FYF condition completed the SCARED at 3 and 6 months post-treatment to 
determine whether reductions in anxiety symptoms were maintained over time. Parent 
Report Forms: Of the 24 parents in the FYF condition who completed the SCARED at 
baseline, 21 completed them at post-intervention (data were imputed for the 3 children who 
dropped out, as baseline scores were carried forward). Three-month follow-up parent report 
was obtained for 20 parents (83.3% of ITT sample); 6-month follow-up reports were 
obtained from 15 parents (62.5%). Child Report Forms: Of the 24 children in the FYF 
condition who completed the SCARED at baseline, 16 (67%) completed the measure at 3 
months and 12 (50%) completed the SCARED at 6-months post-intervention. For those 
returning the follow-up measures, post-intervention reductions appeared to be maintained at 
both 3 and 6 months. See Figure B.
DISCUSSION
Three treatment outcome variables were used to assess the efficacy of the FYF intervention: 
(1) change in anxiety severity and interference of principal diagnoses; (2) change in 
diagnostic status of principal diagnoses; and (3) global rating of improvement in anxiety. 
Children with high-functioning ASD who participated in the FYF intervention demonstrated 
significant reductions in anxiety severity and interference, according to across all four 
principal anxiety diagnoses: SEP, SOC, GAD and SpP. Additionally, participants who 
received the FYF intervention met diagnostic criteria for significantly fewer overall number 
of anxiety diagnoses post-intervention compared with participants in the TAU condition. 
Upon closer examination of each specific anxiety diagnosis, as a group, children in the FYF 
intervention were significantly less likely to meet diagnostic criteria for GAD compared 
with children in the TAU condition. Finally, participants in the FYF condition were 
significantly more likely to meet criteria for a positive treatment response post-treatment 
relative to participants in the TAU condition. In fact, the 50% improvement rate obtained for 
participants in the FYF condition was generally consistent with the results of other studies 
examining the efficacy of CBT (59.7%; Walkup et al., 2008). Reductions in anxiety 
symptoms appeared to be maintained at 3 and 6 months follow-up for the FYF group, 
according to a smaller sample of respondents. Given the overall psychiatric complexity of 
the current sample, the demonstrated gains on the outcome measures are noteworthy.
These findings suggest that a family-focused group CBT intervention developed specifically 
for youth with ASD may be effective for managing anxiety symptoms. The results are 
consistent with our previous work (Reaven et al., 2009) as well as the work of other 
researchers who have demonstrated reductions in anxiety symptoms following the delivery 
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of modified CBT interventions (Chalfant et al. 2006; White et al., 2009; Wood et al., 2009). 
Overall improvement in anxiety symptoms in this study suggests that group treatment for 
youth with ASD may be a feasible and effective modality, and particularly valuable in a 
challenging economic climate. As increasing numbers of youth with ASD and co-occurring 
anxiety present to outpatient clinics across the country, clinicians may be turning to group 
treatments as a way to meet the high demand for services.
It is also notable that significant reductions in GAD diagnoses for participants occurred 
following the FYF intervention. This finding is salient given that the majority of participants 
in this study met diagnostic criteria for a GAD diagnosis pre-intervention. Previous research 
has cited challenges with treatment motivation in participants with a sole diagnosis of GAD 
(Wood et al., 2009).
Limitations and Future Directions
Although the current study implemented a fairly rigorous experimental design (randomized 
assignment, ICE), limitations remain: the sample was primarily Caucasian and relatively 
small, outcome measures normed with typically developing children were used, and there 
was lack of a control group comparable in facilitator time and attention to active treatment. 
Additionally, multiple statistical comparisons were conducted on a relatively small number 
of participants; therefore, caution should be used when interpreting results. Although 
participants who received the FYF intervention experienced significant reductions in 
severity and interference across all four principal anxiety diagnoses, they continued to meet 
diagnostic criteria for SEP, SOC and SpP diagnoses post-intervention. The extent to which 
additional treatment components (e.g., specific social skills modules) are necessary to affect 
change should be explored, along with component analyses to provide information regarding 
the most critical treatment components for youth with ASD. Further, the FYF intervention 
was delivered in a group modality, and although the general pediatric literature indicates that 
group and individual treatment are relatively equivalent with regard to treatment outcome 
for youth with anxiety (Rapee, Wignall, Hudson, & Schniering, 2000), the extent to which 
this is true for youth with ASD is unclear. Head-to-head comparisons of group vs. individual 
treatment approaches for youth with ASD and anxiety are recommended. Finally, larger 
numbers of participants will allow future treatment trials to explore potential moderating 
variables for successful treatment response, such as age, intellectual functioning, severity of 
core autism symptoms, complexity of co-occurring psychiatric conditions, and the presence 
of parent psychopathology.
While the results reflected statistically significant changes in anxiety symptoms, determining 
clinical significance for this psychiatrically complex population is essential (Jacobson, 
Roberts, Berns & McGlinchey, 1999). Improvements in symptoms and decreases in anxiety 
severity may or may not be related to functional outcomes such as school attendance, 
participation in activities outside of school, improved social relationships, age level adaptive 
behaviors and/or quality of life. Ultimately, the most important measure of treatment 
outcome will likely need to include these functional measures of success.
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CONCLUSION
The results of the current study indicated that children with high-functioning ASD, clinical 
anxiety and other psychiatric symptoms demonstrated significant reductions in anxiety 
symptoms following delivery of the FYF intervention. These positive findings contribute to 
a growing body of research demonstrating the benefits of modified CBT for children with 
ASD. More research is needed to identify key components of intervention programs, 
treatment responders, and the extent to which treatment gains observed in the short-term are 
maintained as youth with ASD transition into more complex social and academic 
environments.
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Key Points
• Youth with ASD are at increased risk for developing clinically significant 
anxiety, and these symptoms may markedly impact home, school and 
community settings.
• CBT is an evidence-based psychosocial treatment for anxiety in children.
• Modified CBT approaches have yielded significant reductions in anxiety for 
youth with ASD.
• Participants in the FYF intervention demonstrated significant reductions in 
anxiety severity and greater overall improvement in anxiety, relative to 
participants in the TAU condition.
• These significant findings contribute to the literature demonstrating the benefits 
of modified CBT for youth with ASD.
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Figure A. 
Consort Flow Diagram
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Figure B. 
Parent and child report of Total Anxiety symptoms on the SCARED for the FYF condition: 
Pre-, Post-, 3-month and 6-month follow-up
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Table 1
Participant Characteristics (n = 50)
FYF
n = 24
TAU
n = 26
t p value
Child age (mos.)
 Mean (sd) 125.75 (21.47) 125.00 (20.45) .02 .90
 Range 92 – 164 90 – 168
Full Scale IQ Estimate
 Mean (sd) 107.08 (16.85) 102.23 (17.33) 1.01 .32
 Range 70 – 139 70 – 134
Verbal IQ Estimate
 Mean (sd) 107.00 (19.51) 100.73 (18.98) 1.33 .26
 Range 65 – 133 67 – 134
Nonverbal IQ Estimate
 Mean (sd) 109.67 (16.38) 105.04 (17.86) 1.33 .26
 Range 75 – 133 70 – 134
x2 p value
Child sex (male) 24 (100) 24 (92.3) 1.92 .17
Parents married 20 (83.3) 18 (69.2) 1.36 .24
Mothers graduated from college 15 (62.5) 15 (57.7) .12 .73
Child ethnic background
 Caucasian 22 (91.7) 20 (76.9) 2.36
Yate’s correction: 1.33
.12
Yate’s p value: .08
 Asian/Pacific Islander 0 (0) 1 (3.8) n/a n/a
 African-American 1 (4.2) 2 (7.7) .28 .60
 Multi-racial 1 (4.2) 3 (11.5) .92
Yate’s correction: .19
.34
Yate’s p value: .66
Autism Spectrum Disorder
 Autistic Disorder 16 (67.7) 15 (58.9) .43 .51
 PDD-NOS 0 (0) 3 (11.5) n/a n/a
 Asperger Syndrome 8 (33.3) 8 (30.8) .05 .83
Psychiatric Medication Use – Any 10 14 .74 .28
 SSRI 5 7 .74 .28
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FYF
n = 24
TAU
n = 26
t p value
 Atypical Antipsychotic 4 3 .27 .45
 Stimulant 5 4 .25 .45
 Anticonvulsants 1 3 .92
Yate’s correction: .19
.34
Yate’s p value
 Alpha-blockers 1 5 n/a n/a
 Mood stabilizers 0 1 n/a n/a
Psychiatric Medications Stable across intervention period 23 23 .92 .34
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